BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211118
DTEND;VALUE=DATE:20211219
DTSTAMP:20260515T231521
CREATED:20211018T092817Z
LAST-MODIFIED:20211018T092817Z
UID:31844-1637193600-1639871999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect 2021
DESCRIPTION:Virtual Expo Connect” is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. Powered by PharmaSources.com\, Virtual Expo Connect builds an online platform to be accessed from anywhere\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://bit.ly/3ASODPZ
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2021/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Candice.lau@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211130
DTEND;VALUE=DATE:20211203
DTSTAMP:20260515T231521
CREATED:20210813T092849Z
LAST-MODIFIED:20210813T092849Z
UID:31293-1638230400-1638489599@www.pharmajournalist.com
SUMMARY:Cytokine-Based Cancer Immunotherapies Summit Boston
DESCRIPTION:The only in person dedicated industry forum supporting the development of robust cytokine-based cancer immunotherapy platforms (cytokine muteins\, antibody-cytokine fusion proteins (immunokines)\, anticancer vaccines\, and cancer-directed antibodies) to deliver targeted\, durable therapeutic interventions to solid tumor and hematological cancer indications. \nThis comprehensive\, drug development focused agenda will showcase the latest concepts and molecular engineering approaches being utilized by biopharma and research groups to help you overcome the challenges in: \n\nToxicity management – engineering selectivity\, targeting and half life modulation\nOptimizing the risk benefit by dose and schedule optimization\nAchieving safe and acceptable delivery\nUnderstanding the potentials for combination\nDelving into the clinical data to understand the translational side\n\nYou will have the opportunity to join a pre-conference workshop day exploring pre-clinical models for cytokine research and the world of cytokines in inflammatory disease\, providing insight into where the world of cytokine research is going beyond oncology. \nJoin this exclusive community of cytokine pioneers to network and learn from the leading experts in pharma\, biotech and academia\, as we discuss how to successfully and safely deliver cytokine therapies to a plethora of cancer indications. \nAcross 3 content packed days\, 30+ experts will converge to discuss novel cytokines\, the shortfalls of these therapies and how to learn from the pitfalls of the first cytokine era – this is not one to miss! \nTo know more visit: https://ter.li/gwz2x1
URL:https://www.pharmajournalist.com/event/cytokine-based-cancer-immunotherapies-summit-boston/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211130
DTEND;VALUE=DATE:20211203
DTSTAMP:20260515T231521
CREATED:20210820T103831Z
LAST-MODIFIED:20210820T103831Z
UID:31382-1638230400-1638489599@www.pharmajournalist.com
SUMMARY:Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:Marrying unmissable insights from global renal experts\, the 1st Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to provide you with transformative perspectives from identifying genetic drivers of rare kidney diseases to innovative trial design in small disease populations to accelerate progress of your genetic kidney disease pipeline. \nHear from industry heavyweights including Sanofi Genzyme\, Alexion\, AstraZeneca\, Regulus Therapeutics\, Chinook Therapeutics\, Ionis Pharmaceuticals\, Novartis\, Otsuka Pharmaceutical Companies and many more to ignite your entry to the rare and genetic kidney disease landscape and confidently progress from proof of concept to the clinic. \nDiscover pivotal advances in disease modelling with stem cell-derived kidney organoids\, explore opportunities for comprehensive genetic diagnosis and patient stratification\, and join the conversation on progressing surrogate biomarkers and endpoints to guide strategic decisions on your pipeline in ADPKD\, Alport Syndrome and more. \nGet involved to understand why interest in rare and genetic kidney diseases is exploding and keep up to date with the latest opportunities for genetic intervention. \nTo know more visit: https://ter.li/k0fu1i
URL:https://www.pharmajournalist.com/event/rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR